{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:51Z","timestamp":1793196591403,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40265-023-01991-5","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T21:02:35Z","timestamp":1708635755000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Vonoprazan: A Review in Helicobacter pylori Infection"],"prefix":"10.1007","volume":"84","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"2","key":"1991_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2016.563","volume":"112","author":"WD Chey","year":"2017","unstructured":"Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212\u201339.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1991_CR2","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","volume":"71","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022;71(9):1724\u201362.","journal-title":"Gut"},{"issue":"4","key":"1991_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/17474124.2022.2056015","volume":"16","author":"S Shah","year":"2022","unstructured":"Shah S, Hubscher E, Pelletier C, et al. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Rev Gastroenterol Hepatol. 2022;16(4):341\u201357.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"1991_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","volume":"160","author":"SC Shah","year":"2021","unstructured":"Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160(5):1831\u201341.","journal-title":"Gastroenterology"},{"issue":"6","key":"1991_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1523-5378.2002.00105.x","volume":"7","author":"JI Kim","year":"2002","unstructured":"Kim JI, Park SH, Kim JK, et al. The effects of nocturnal acid breakthrough on Helicobacter pylori eradication. Helicobacter. 2002;7(6):331\u20136.","journal-title":"Helicobacter"},{"issue":"1","key":"1991_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/00365529850166185","volume":"33","author":"S Sj\u00f6stedt","year":"1998","unstructured":"Sj\u00f6stedt S, Sagar M, Lindberg G, et al. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol. 1998;33(1):39\u201343.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"1991_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1523-5378.2007.00508.x","volume":"12","author":"M Sugimoto","year":"2007","unstructured":"Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12(4):317\u201323.","journal-title":"Helicobacter"},{"issue":"F1000 Faculty R","key":"1991_CR8","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.12688\/f1000research.8598.1","volume":"5","author":"DR Scott","year":"2016","unstructured":"Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res. 2016;5(F1000 Faculty Rev):1747.","journal-title":"F1000Res"},{"issue":"1","key":"1991_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11938-020-00330-x","volume":"19","author":"C Scarpignato","year":"2021","unstructured":"Scarpignato C, Hunt RH. Acid suppressant therapy: a step forward with potassium-competitive acid blockers. Curr Treat Options Gastro. 2021;19(1):94\u2013132.","journal-title":"Curr Treat Options Gastro."},{"issue":"1","key":"1991_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3164\/jcbn.17-128","volume":"63","author":"K Ohkuma","year":"2018","unstructured":"Ohkuma K, Iida H, Inoh Y, et al. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr. 2018;63(1):80\u20133.","journal-title":"J Clin Biochem Nutr."},{"issue":"6","key":"1991_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1991_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","volume":"117","author":"L Laine","year":"2022","unstructured":"Laine L, Sharma P, Mulford DJ, et al. Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects. Am J Gastroenterol. 2022;117(7):1158\u201361.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1991_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439\u201343.","journal-title":"Drugs"},{"issue":"3","key":"1991_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","volume":"163","author":"WD Chey","year":"2022","unstructured":"Chey WD, M\u00e9graud F, Laine L, et al. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608\u201319.","journal-title":"Gastroenterology"},{"key":"1991_CR15","unstructured":"Phathom Pharmaceuticals Inc. Voquezna Triple Pak (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets) and Voquezna Dual Pak (vonoprazan tablets; amoxicillin capsules): US prescribing information. 2023. https:\/\/www.phathompharma.com\/wp-content\/uploads\/VOQUEZNA-TRIPLE-PAK-and-VOQUEZNA-DUAL-PAK-FDA-Final-Label-3.pdf. Accessed 19 Dec 2023."},{"key":"1991_CR16","unstructured":"Phathom Pharmaceuticals Inc. Voquezna (vonoprazan) tablets: US prescribing information. 2023. https:\/\/www.phathompharma.com\/wp-content\/uploads\/VOQUEZNA-tablets-Prescriber-Information.pdf. Accessed 19 Dec 2023."},{"issue":"2","key":"1991_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412\u201320.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"1991_CR18","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636\u201348.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"1991_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/apt.12059","volume":"36","author":"EA Marcus","year":"2012","unstructured":"Marcus EA, Inatomi N, Nagami GT, et al. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther. 2012;36(10):972\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1991_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s11894-011-0226-4","volume":"13","author":"G Sachs","year":"2011","unstructured":"Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep. 2011;13(6):540\u20136.","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"1991_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11\u201312","key":"1991_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"DR Scott","year":"2015","unstructured":"Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015;42(11\u201312):1315\u201326.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1991_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpdd.1009","volume":"11","author":"DJ Mulford","year":"2022","unstructured":"Mulford DJ, Leifke E, Hibberd M, et al. The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev. 2022;11(2):278\u201384.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"12","key":"1991_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","volume":"47","author":"H Yamasaki","year":"2017","unstructured":"Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017;47(12):1027\u201334.","journal-title":"Xenobiotica"},{"issue":"6","key":"1991_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6(6): e94.","journal-title":"Clin Transl Gastroenterol"},{"issue":"6","key":"1991_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/jcph.2019","volume":"62","author":"C Scarpignato","year":"2022","unstructured":"Scarpignato C, Leifke E, Smith N, et al. A population pharmacokinetic model of vonoprazan: evaluating the effects of race, disease status, and other covariates on exposure. J Clin Pharmacol. 2022;62(6):801\u201311.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1991_CR27","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s12325-016-0374-x","volume":"33","author":"Y Sakurai","year":"2016","unstructured":"Sakurai Y, Shiino M, Okamoto H, et al. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study. Adv Ther. 2016;33(9):1519\u201335.","journal-title":"Adv Ther"},{"issue":"7 suppl","key":"1991_CR28","doi-asserted-by":"publisher","first-page":"S-544","DOI":"10.1016\/S0016-5085(22)61292-7","volume":"162","author":"D Ramsden","year":"2022","unstructured":"Ramsden D, Mulford DJ, Zhang L, et al. Novel approach to evaluate the impact of moderate and strong CYP3A inducers on vonoprazan exposure [abstract Su1203 and poster]. Gastroenterology. 2022;162(7 suppl):S-544.","journal-title":"Gastroenterology"},{"issue":"3","key":"1991_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40261-016-0488-6","volume":"37","author":"H Jenkins","year":"2017","unstructured":"Jenkins H, Jenkins R, Patat A. Effect of multiple oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan: a phase I, open-label, sequential design study. Clin Drug Investig. 2017;37(3):311\u20136.","journal-title":"Clin Drug Investig"},{"issue":"7 suppl","key":"1991_CR30","doi-asserted-by":"publisher","first-page":"S-545","DOI":"10.1016\/S0016-5085(22)61294-0","volume":"162","author":"DJ Mulford","year":"2022","unstructured":"Mulford DJ, Brudi P, Smith N, et al. A clinical drug interaction study to assess the effect of vonoprazan on the pharmacokinetics of midazolam [abstract Su1205 and poster]. Gastroenterology. 2022;162(7 suppl):S-545.","journal-title":"Gastroenterology"},{"issue":"4385161","key":"1991_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4385161","volume":"2017","author":"M Maruyama","year":"2017","unstructured":"Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol. 2017;2017(4385161):1\u20137.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"9","key":"1991_CR32","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439\u201346.","journal-title":"Gut"},{"issue":"11","key":"1991_CR33","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2169\/internalmedicine.56.7833","volume":"56","author":"S Sue","year":"2017","unstructured":"Sue S, Kuwashima H, Iwata Y, et al. The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study on Helicobacter pylori eradication. Intern Med. 2017;56(11):1277\u201385.","journal-title":"Intern Med"},{"issue":"e12456","key":"1991_CR34","first-page":"1","volume":"23","author":"S Sue","year":"2018","unstructured":"Sue S, Ogushi M, Arima I, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter. 2018;23(e12456):1\u20138.","journal-title":"Helicobacter"},{"issue":"4","key":"1991_CR35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/jgh.14456","volume":"34","author":"S Sue","year":"2019","unstructured":"Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019;34(4):686\u201392.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"1991_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019\u201326.","journal-title":"Gut"},{"issue":"7","key":"1991_CR37","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/jgh.15837","volume":"37","author":"X Hou","year":"2022","unstructured":"Hou X, Meng F, Wang J, et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. J Gastroenterol Hepatol. 2022;37(7):1275\u201383.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"1991_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/apt.17070","volume":"56","author":"D Ang","year":"2022","unstructured":"Ang D, Koo SH, Chan YH, et al. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther. 2022;56(3):436\u201349.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1991_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12970","volume":"28","author":"J Hu","year":"2023","unstructured":"Hu J, Mei H, Su NY, et al. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China. Helicobacter. 2023;28(4): e12970.","journal-title":"Helicobacter"},{"key":"1991_CR40","doi-asserted-by":"publisher","first-page":"1049908","DOI":"10.3389\/fimmu.2022.1049908","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, Xu X, Liu XS, et al. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022;13:1049908.","journal-title":"Front Immunol"},{"issue":"41","key":"1991_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035610","volume":"102","author":"F Yang","year":"2023","unstructured":"Yang F, Yu B, Qin L, et al. A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori. Medicine (Baltimore). 2023;102(41): e35610.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1991_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/apt.14130","volume":"46","author":"YS Jung","year":"2017","unstructured":"Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46(2):106\u201314.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1991_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000504939","volume":"102","author":"S Shinozaki","year":"2021","unstructured":"Shinozaki S, Kobayashi Y, Osawa H, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion. 2021;102(3):319\u201325.","journal-title":"Digestion"},{"issue":"e12495","key":"1991_CR44","first-page":"1","volume":"23","author":"M Li","year":"2018","unstructured":"Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23(e12495):1\u20138.","journal-title":"Helicobacter"},{"issue":"7","key":"1991_CR45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/jcpt.13637","volume":"47","author":"C Yang","year":"2022","unstructured":"Yang C, Li S, Huang T, et al. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2022;47(7):897\u2013904.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"1991_CR46","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.gastha.2022.06.009","volume":"1","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Moss SF, Daniele P, et al. Potassium-competitive acid blocker and proton pump inhibitor-based regimens for first-line Helicobacter pylori eradication: a network meta-analysis. Gastro Hep Adv. 2022;1(5):824\u201334.","journal-title":"Gastro Hep Adv."},{"issue":"2","key":"1991_CR47","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00228-022-03430-y","volume":"79","author":"Y Sun","year":"2023","unstructured":"Sun Y, Yue L, Hu W. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol. 2023;79(2):279\u201388.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"1991_CR48","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353\u201367.","journal-title":"Gut"},{"issue":"3","key":"1991_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1053\/j.gastro.2022.06.076","volume":"163","author":"CA Fallone","year":"2022","unstructured":"Fallone CA. The current role of vonoprazan in Helicobacter pylori treatment. Gastroenterology. 2022;163(3):572\u20134.","journal-title":"Gastroenterology"}],"updated-by":[{"DOI":"10.1007\/s40265-024-02042-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01991-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01991-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01991-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T03:20:05Z","timestamp":1715656805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01991-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1991"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01991-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"20 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-024-02042-3","URL":"https:\/\/doi.org\/10.1007\/s40265-024-02042-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}